A study published in JAMA Internal Medicine on April 7, 2026 analyzed 4.8 million patient records to assess the impact of Medicare's $35 monthly insulin cap, which was implemented five years earlier for type 2 diabetes patients. The research found that the price cap significantly reduced out-of-pocket spending, increased insulin use, and improved blood sugar control as measured by two-to-three month averages, though severe hypoglycemia events saw a small increase. The findings provide evidence for price control policies amid a context where insulin prices tripled between 2002 and 2013. The study demonstrates that affordability interventions can improve both medication adherence and clinical outcomes for diabetes patients.
Story comments
Loading comments…